| Nov 19 |
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary
|
| Nov 12 |
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
|
| Nov 6 |
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
|
| Oct 31 |
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
|
| Oct 14 |
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
|
| Oct 11 |
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
|
| Oct 2 |
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
|
| Sep 30 |
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
|
| Sep 23 |
Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
|
| Jul 31 |
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
|
